RTP Mobile Logo
Second Opinion: Proceedings from an Interactive Case-Based Symposium on the Management of Patients with Early and Advanced Breast Cancer
Released April 2012

Proceedings from a case-based symposium preceding the 34th San Antonio Breast Cancer Symposium. Featuring perspectives from Drs Julie R Gralow, Hope S Rugo, George W Sledge Jr, Ian E Smith and Eric P Winer. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical, surgical and radiation oncologists and other healthcare providers involved in the treatment of breast cancer.

    OVERVIEW OF ACTIVITY

    Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. To bridge the gap between research and patient care, these proceedings from a case-based CME satellite symposium at the 2011 San Antonio Breast Cancer Symposium use the perspectives of clinical investigators, in addition to the exchange among these individuals, to apply evidence-based concepts to routine practice. By providing access to the latest research developments and expert opinions on the disease, this activity will assist medical, surgical and radiation oncologists in the formulation of up-to-date clinical management strategies for breast cancer.

    LEARNING OBJECTIVES

    • Integrate validated genomic assays into the clinical management of estrogen receptor (ER)-positive, node-negative and node-positive early breast cancer.
    • Assimilate new clinical trial evidence into the therapeutic algorithm for advanced ER-positive breast cancer.
    • Demonstrate knowledge of emerging research to support alternative or novel chemotherapeutic regimens in the adjuvant and metastatic settings, and integrate these findings into best-practice disease management strategies.
    • Apply the results of emerging research to effectively integrate HER2-directed treatments into the systemic management of both early and advanced HER2-overexpressing breast cancer.
    • Recall the results of pivotal trials introducing effective new breast cancer therapeutics, and identify their impact on existing treatment algorithms.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Julie R Gralow, MD

    Professor, Medical Oncology
    University of Washington and Fred Hutchinson Cancer Research Center
    Director, Breast Medical Oncology
    Seattle Cancer Care Alliance/University of Washington
    Seattle, Washington

    Paid Research: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

    Steven W Papish, MD
    Medical Director
    Carol G Simon Cancer Center
    Morristown Medical Center
    Morristown, New Jersey

    Speakers Bureau: Genentech BioOncology, Genomic Health Inc.

    Alejandra T Perez, MD
    Director, Breast Cancer Centers
    Memorial Cancer Institute
    Hollywood, Florida

    No real or apparent conflicts of interest to disclose.

    Frank A Rodriguez, MD
    Florida Cancer Specialists
    Fort Myers, Florida

    Speakers Bureau: Celgene Corporation, GlaxoSmithKline, Millennium: The Takeda Oncology Company.

    Hope S Rugo, MD

    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Paid Research: Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Speakers Bureau: Genomic Health Inc.

    George W Sledge Jr, MD
    Ballve-Lantero Professor of Oncology
    Professor of Medicine and Pathology
    Co-Director of the IUSCC Breast Cancer Research Program
    Indiana University Simon Cancer Center
    Indiana University School of Medicine
    Indianapolis, Indiana

    No real or apparent conflicts of interest to disclose.

    Ian E Smith, MD
    Professor of Cancer Medicine
    Head of the Breast Unit
    The Royal Marsden Hospital and Institute of Cancer Research
    London, United Kingdom

    Advisory Committee and Consulting Agreements: Lilly USA LLC, Roche Laboratories Inc; Speakers Bureau: Sanofi.

    Eric P Winer, MD
    Thompson Investigator in Breast Cancer Research
    Chief, Division of Women’s Cancers
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Novartis Pharmaceuticals Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2012
    Expiration date: April 2013

Acknowledge and close

Watch video
(WiFi is recommended for best performance):
Introduction: Dr Love
Module 1:
Faculty
A Patient with 2 Primary Cancers
Module 2:
Dr Winer
HER2-Positive Breast Cancer Treatment
Module 3:
Dr Gralow
Cytotoxic and Biologic Treatments
Module 4:
Dr Sledge
Multigene Assays in Practice
Module 5:
Dr Rugo
Advances in ER-Positive Breast Cancer
Module 6:
Dr Smith
HER2-Positive Early Breast Cancer